Hims & Hers
also referred to as: hims & hers health
6 statements across 3 episodes · 2 bullish · 3 bearish · 2 people on the record · first statement Nov 19, 2024 by Jordi Hays · said 67 times in 7 episodes since 2024 · across every show →
Mentions by year
brought up most by John Coogan (52), Jordi Hays (13), Logan Bartlett (1)
tap a year for its mentions
2026 2 mentions in 2 episodes 1 per episode
2025 60 mentions in 4 episodes 15 per episode
- Weekly Recap: Tesla Robotaxi, Mr. Beast's AI Tool, Yacine, The Social Network 2, Neuralink Update
- REVIEW: HIMS Super Bowl Ad (Controversy)
- What the New TARIFFS Mean for Tech | Logan Bartlett on TBPN April 7th
- DeepSeek, Stargate Update, Bees Do Enjoy Honey, Golden Retriever Maxxing, Bring on the Trilly
- every mention in 2025, scene by scene →
2024 5 mentions in 1 episode
Everything said about Hims & Hers, oldest first
Nov 19, 2024 bullish
Feb 12, 2025 bearish
Coogan: Novo Nordisk supply will eventually severely limit compounded GLP-1s
“It may take a few more quarters, but Novo Nordisk will eventually produce enough supply to end the shortage of its drug. When that happens, despite their efforts to influence public opinion, Compounded versions will likely be severely limited.”
Feb 12, 2025 bullish
Feb 12, 2025 negative
Coogan: Telehealth compounding stretches regulations meant for local pharmacies
“Compounding pharmacy regulations were written for, hey, your town might have a local pharmacist, and in a shortage, you should be able to walk down to the pharmacy, and they should be able to make you know, something that they can't otherwise buy, and then thi…”
Feb 12, 2025 neutral
Hims bends rules because GLP-1 cash outweighs risks, says Hays
“Yes, of course they're bending the rules around compounding and like, but they seem to be okay with that risk appetite because they're printing so much cash off of this that they're like, it's one of those situations where they're like, even if we get, you kno…”
Jun 28, 2025 negative
Coogan: Hims & Hers drops record 32% after Novo Nordisk split
“News that the deal was scrapped weighed heavily on Hims and Herb's shares, sending them down 32% in afternoon trading in what would be the largest decline for the stock on record. Novo Nordisk's shares were down nearly six percent in New York.”